(F) Schematic and genetic construction of avelu-MD5-1 bispecific antibody that contains anti-PD-L1 (Avelumab), anti-muDR5 (MD5-1) heavy/light (VH/VL) variable domains (blue and dark red respectively. Both monospecific and bispecific antibodies contain LALA mutation to avoid interference with Fc-effector function. CK: C-kappa, CH1: Constant heavy chain 1, CH2: Constant heavy chain 2, CH3: Constant heavy chain 3. Dark blue dotted line under CH3 and between MD5-1 VH and VL depicts flexible linker. 